Archive for March, 2017

$ERS Enters Into Merger Agreement With Ta Chen

FORT LEE, N.J., March 31, 2017 — Empire Resources, Inc. (NASDAQ: ERS), a distributor of value added, semi-finished metal products, announced today that it has entered into a definitive merger agreement to be acquired for $7.00 per share in cash by a unit of Ta Chen Stainless Pipe Co., Ltd., a leading master distributor of stainless, aluminum and nickel alloy products. The acquisition will be completed by means of a tender offer for all outstanding Empire shares. The tender offer will be followed by a merger in which all shares not acquired in the tender offer will be converted into the right to receive the offer price. The acquisition is subject to customary conditions, including the tender of shares resulting in Ta Chen’s ownership of a majority of the fully diluted shares of Empire.

The $7.00 per share price represents a premium of approximately 19.2% percent over Empire’s average closing price during the three month  trading period ending March 30, 2017.

The aggregate value of the transaction is approximately $58 million for all of the outstanding shares of Empire. The Empire Board of Directors has unanimously approved the agreement.

Nathan Kahn, President and Chief Executive Officer of Empire, commented: “This agreement with Ta Chen represents the culmination of our effort to unlock the substantial value of Empire for our shareholders while creating a combined company with highly complementary strengths and greater resources for the benefit of our customers and employees.

“We believe that customers of both companies will benefit from Empire’s recognized service levels and Ta Chen’s excellent internet platform, just-in-time delivery capabilities and its extensive warehouse network in the U.S. I am pleased to note that under the agreement, Empire will operate as a wholly-owned subsidiary of Ta Chen, with Empire’s current team unchanged and reporting structure intact over the coming year.”

Nathan Kahn and Sandra Kahn, Vice President and Chief Financial Officer of Empire, who together own approximately 46.3% percent of the Company’s outstanding shares, have agreed to tender their shares into the offer. Ta Chen owns approximately five percent of Empire’s common stock prior to this announcement. The closing of the tender offer is subject to customary closing conditions. The transaction is expected to close in the second quarter of 2017. There can be no assurance that the tender offer will be completed, or if completed, that it will be completed in the second quarter of 2017.

Harpeth Capital LLC served as financial advisor to Empire Resources and provided a fairness opinion to the board of directors in connection with the transaction.

About Empire Resources, Inc.

Empire Resources, Inc. is a distributor of a wide range of semi-finished metal products to customers in the transportation, automotive, housing, appliance and packaging industries in the U.S., Canada, Australia, New Zealand and Europe. The Company maintains supply contracts with mills in various parts of the world.

Forward-Looking Statements:

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the loss or default of one or more suppliers; (ii) the loss or default of one or more significant customers; (iii) a default by counterparties to derivative financial instruments; (iv) changes in general, national or regional economic conditions; (v) an act of war or terrorism that disrupts international shipping; (vi) changes in laws, regulations and tariffs; (vii) the imposition of anti-dumping duties on products the Company imports; (viii) changes in the size and nature of the Company’s competition; (ix) changes in interest rates, foreign currencies or spot prices of aluminum; (x) the loss of one or more key executives; (xi) increased credit risk from customers; (xii) the Company’s failure to grow internally or by acquisition and (xiii) the Company’s failure to improve operating margins and efficiencies. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Notice to Investors:  

The tender offer for the outstanding common stock of Empire Resources referred to in this press release has not yet commenced. This press release is neither an offer to purchase nor a solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of the Company common stock will be made pursuant to an offer to purchase and related materials that Ta Chen intends to file with the Securities and Exchange Commission. At the time the offer is commenced, Ta Chen will file a tender offer statement on Schedule TO with the Securities and Exchange Commission, and thereafter the Company will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. The tender offer statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement, as they may be amended from time to time, will contain important information that should be read carefully and considered before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of Empire Resources when available. In addition, all of these materials (and all other materials filed by the Company with the Securities and Exchange Commission) will be available at no charge from the Securities and Exchange Commission through its website at www.sec.gov.

Friday, March 31st, 2017 Uncategorized Comments Off on $ERS Enters Into Merger Agreement With Ta Chen

$BBRY From Smartphones to Smart Enterprises: Blackberry Targets the Enterprise of Things

WATERLOO, ONTARIO–(March 31, 2017) – BlackBerry Limited (NASDAQ:BBRY) (TSX:BB) today shared new details on its broad licensing strategy which addresses the growing need for secure, connected devices and endpoints in today’s Enterprise of Things.

The first phase of BlackBerry’s strategy, announced in September 2016, was focused on providing the most secure and comprehensive Android software for smartphones around the world manufactured and marketed by TCL Communication, PT BB Merah Putih and Optiemus Infracom Ltd. The company is now pursuing additional endpoints which could include tablets, wearables, medical devices, appliances, point-of-sale terminals and other smartphones.

“There is an incredible opportunity for connected devices to improve lives, but to realize its full potential, privacy and security must be embedded in every end point from the start. For example, companies providing medical monitoring devices must protect health data on the device, guarantee it connects securely to the healthcare system, and most importantly ensure that it cannot be hacked, BlackBerry Secure helps solve this triple threat,” said John Chen, Executive Chairman and CEO, BlackBerry. “We have taken a long-term and thoughtful approach to our licensing strategy, which includes an expansive view of the entire Enterprise of Things ecosystem. As part of this strategy, we will work with a wide range of manufacturers to integrate BlackBerry Secure software into both BlackBerry-branded and co-branded devices.”

For more information, please email bbsecure@blackberry.com.

About BlackBerry

BlackBerry is a mobile-native security software and services company dedicated to securing people, devices, processes and systems for today’s enterprise. Based in Waterloo, Ontario, the company was founded in 1984 and operates in North America, Europe, Asia, Middle East, Latin America and Africa. The Company trades under the ticker symbols “BB” on the Toronto Stock Exchange and “BBRY” on the NASDAQ. For more information, visit www.BlackBerry.com.

Forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used herein, words such as “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend”, “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements are based on estimates and assumptions made by BlackBerry Limited in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that BlackBerry believes are appropriate in the circumstances. Many factors could cause BlackBerry’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of BlackBerry’s Annual Information Form, which is included in its Annual Report on Form 40-F (copies of which filings may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on BlackBerry’s forward-looking statements. BlackBerry has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

BlackBerry and related trademarks, names and logos are the property of BlackBerry Limited and are registered and/or used in the U.S. and countries around the world. All other marks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.

BlackBerry Media Contact:
BlackBerry Media Relations
(519) 597-7273
mediarelations@BlackBerry.com

BlackBerry Investor Contact:
BlackBerry Investor Relations
(519) 888-7465
investor_relations@BlackBerry.com

Friday, March 31st, 2017 Uncategorized Comments Off on $BBRY From Smartphones to Smart Enterprises: Blackberry Targets the Enterprise of Things

$LTRX to Present at the MicroCap Conference on April 4, 2017

IRVINE, Calif., March 31, 2017  — In a release issued yesterday by Lantronix, please note that in the headline and first paragraph of the release, the presentation date should be April 4, not April 3 as previously stated. The corrected release follows:

Lantronix, Inc. (NASDAQ:LTRX), a global provider of secure data access and management solutions for Internet of Things (IoT) and information technology (IT) assets, today announced that President and CEO Jeff Benck, and CFO Jeremy Whitaker will present at the MicroCap Conference on Monday, April 4, 2017 at 8:30 AM Eastern Time (5:30 AM Pacific Time) at the Essex House in New York City. A live webcast and copy of the Company’s slide presentation will be available on the investor relations section of the Company’s website at www.lantronix.com.

Investors attending the conference who wish to meet with Lantronix management should contact E.E. Wang at investors@lantronix.com.

About Lantronix 
Lantronix, Inc. is a global provider of secure data access and management solutions for Internet of Things (IoT) and information technology (IT) assets. Our mission is to be the leading supplier of IoT gateways that enable companies to dramatically simplify the creation, deployment and management of IoT projects while providing secure access to data for applications and people.

With more than two decades of experience in creating robust machine to machine (M2M) technologies, Lantronix is an innovator in enabling our customers to build new business models and realize the possibilities of the Internet of Things. Our connectivity solutions are deployed inside millions of machines serving a wide range of industries, including data center, medical, security, industrial, transportation, retail, financial, environmental and government.

Lantronix is headquartered in Irvine, California, with offices in Europe and Asia. For more information, visit www.lantronix.com.

Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.

© 2017 Lantronix, Inc. All rights reserved.

Lantronix Contact:        
E.E. Wang
Director, Corporate Marketing and Investor Relations
investors@lantronix.com
ee.wang@lantronix.com 
949-614-5879

Jeremy Whitaker
Chief Financial Officer
investors@lantronix.com
Friday, March 31st, 2017 Uncategorized Comments Off on $LTRX to Present at the MicroCap Conference on April 4, 2017

$CIDM Announces Major OTT Platform Expansions For 2017

OTT Channel reach to expand by 60+ Million New Consumers on Google’s Chromecast, Android TV, and Amazon Fire TV Platforms

Cinedigm (NASDAQ: CIDM) announced today plans to significantly extend the availability of its fast-growing OTT services by supporting Google’s Chromecast and Android TV Platforms, as well as Amazon Fire TV for the first time.

The expansion will begin with Google Chromecast, with availability scheduled for April 21st, 2017. This will be followed by Amazon Fire TV support, releasing in June 2017, and Android TV, releasing in July 2017. Cinedigm’s OTT channels can currently be viewed across a broad spectrum of connected devices including Roku Players and Roku TV models, Android, Apple’s iOS and tvOS, and all major web browsers. Additionally, Cinedigm’s channels are available to Amazon Prime members as part of Amazon’s Streaming Partners Program.

These expansions will extend Cinedigm’s OTT Channel reach by more than 60 Million new devices. According to research firm eMarketer, Chromecast is the most popular OTT device in the US, with more than 30 million users, and Amazon’s Fire TV is the fastest-growing connected device platform. Additionally, Google’s Android TV platform has exceeded 50% market share of new Smart TV shipments, according to IHS Research.

The addition of Android TV will significantly expand Cinedigm’s Connected TV footprint, reaching major manufacturers including Sharp, Sony, Phillips, RCA, Hisense and TCL, among others.

“Given the success of our networks on Roku, iOS and Android to date, it is our number one priority to extend the reach of our world-class channels, Dove, CONtv, Docurama and Wham,” said Erick Opeka, EVP of Digital Networks for Cinedigm. “Adding these platforms expands our reach to over 90% of the connected device market, and gives our existing user base expanded choices to enjoy their content where, when and how they want.”

In addition to the aforementioned platform expansions, Cinedigm will be releasing upgraded versions of its iOS and Android applications. The new versions will provide simplified subscription processes and enhanced user engagement features, and will be available in May 2017.

“This expansion follows the tremendous progress we have seen in our OTT channels over the last few months, including our rollout on Apple TV, our upgraded interface and the exciting announcement of our newest channel focused on gaming and e-sports, The WHAM Network,” continued Opeka.

Cinedigm has also recently added MPAA-grade digital rights management to support the recent licensing of over 150 hours of high-quality Studio programming.

Cinedigm channels include:

Dove Channel: targeting the family values audience with movies and shows families can enjoy together. The content offering includes mainstream and classic family movies, documentaries, heartwarming TV series and children’s programs. All of Dove Channel’s carefully curated content reflects the time-honored standards of The Dove Foundation and its trusted Family Seal of Approval.

CONtv: catering to the enormous and avid Comic Con audience. The channel currently boasts 2,500 hours of original programming, curated films and TV episodes, and exclusive Comic Con panel coverage from dozens of annual nationwide conventions.

Docurama: targeted to the avid documentary audience with over 1,200 titles, including full-length and short-form documentaries, non-fiction TV programming, and behind-the-scenes interviews.

The WHAM Network: providing news, information and entertainment 24/7 focused on the fast growing global e-sports and gaming audience. Launches Fall 2017.

About Cinedigm

Cinedigm powers custom content solutions to the world’s largest retail, media and technology companies. We provide premium feature films and series to digital platforms including iTunes, Netflix, and Amazon, cable and satellite providers including Comcast, Dish Network and DirecTV, and major retailers including Walmart and Target. Leveraging Cinedigm’s unique capabilities, content and technology, the Company has emerged as a leader in the fast-growing over-the-top channel business, with four channels under management that reach hundreds of millions of devices while also providing premium content and service expertise to the entire OTT ecosystem.

[CIDM-G]

 

Cinedigm
Jill Newhouse Calcaterra, 310-466-5135
jcalcaterra@cinedigm.com

Friday, March 31st, 2017 Uncategorized Comments Off on $CIDM Announces Major OTT Platform Expansions For 2017

$NVCR Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields

Interim results from the STELLAR trial, presented in December 2016, suggest improvements in progression free survival and one-year survival rates when TTFields is added to standard chemotherapy

Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the STELLAR trial, a phase 2 pilot trial testing Tumor Treating Fields (TTFields) in combination with either pemetrexed and cisplatin or carboplatin in patients with newly diagnosed, unresectable malignant mesothelioma. The final data collection date will be 12 months after the last patient in.

“The interim data presented at International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer were extremely encouraging in a disease where a significant unmet need clearly remains,” said Dr. Uri Weinberg, Novocure’s Vice President of Research and Development. “The one-year survival rates of patients treated with TTFields combined with pemetrexed and cisplatin or carboplatin were more than 50% greater than historical control data.”

The open-label trial includes 80 patients with unresectable, previously untreated malignant mesothelioma. STELLAR’s primary endpoint is overall survival and secondary endpoints are progression free survival, response rate, and treatment-emergent toxicity.

“We look forward to seeing the final results from the STELLAR trial,” said Asaf Danziger, Novocure’s CEO. “The interim data give us hope that TTFields used in combination with standard of care chemotherapies may increase survival for patients with mesothelioma without significantly increasing side effects.”

Treatment with Tumor Treating Fields (TTFields) is not approved for mesothelioma. The safety and effectiveness of treatment with TTFields for mesothelioma has not been established.

About Mesothelioma

Malignant mesothelioma is a rare thoracic solid tumor cancer that occurs in approximately 3,000 patients in the United States annually. Asbestos exposure has been strongly associated with the development of mesothelioma, which may occur many years following the exposure. The prognosis of mesothelioma patients is very poor, with a median overall survival of approximately 12 months in most reported studies.

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment centered on a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

 

Novocure
Media and Investor Contact:
Ashley Cordova, 212-767-7558
acordova@novocure.com

Friday, March 31st, 2017 Uncategorized Comments Off on $NVCR Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields

$STDY Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

U.S. Patent Trial and Appeal Board Cancels all claims in United Therapeutics’ ‘393 patent for purification of prostacyclin derivatives, rendering patent invalid.

SteadyMed plans to file New Drug Application (NDA) for Trevyent® for the treatment of Pulmonary Arterial Hypertension (PAH) in Q2 2017

SAN RAMON, Calif., March 31, 2017 — SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 8,497,393 (the ‘393 patent) owned by United Therapeutics. In its ruling, the PTAB found all 22 claims in the ‘393 patent unpatentable and cancelled them, rendering the patent invalid.

The IPR was instituted by PTAB in April 2016 after SteadyMed challenged the ‘393 patent’s validity. The ‘393 patent claims a product made by a process to further purify prostacyclin derivatives, such as treprostinil. Treprostinil is the active pharmaceutical ingredient used in United Therapeutics’ Remodulin® and SteadyMed’s lead drug candidate, Trevyent, which is in development for the treatment of Pulmonary Arterial Hypertension (PAH).

“We are very pleased with this decision by the PTAB, which confirms our position that the claims in the ‘393 patent were invalid and the patent should not have been issued to United Therapeutics,” said Jonathan Rigby, President and Chief Executive Officer of SteadyMed. “We continue to focus on completing the final steps ahead of submitting our New Drug Application (NDA) for Trevyent, for the treatment of PAH, by the end of the second quarter. We have a growing body of market research data that we believe strongly indicates a significant need for Trevyent that, if approved, has the potential to take a meaningful share of the PAH market.”

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company’s lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed’s PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements about the company’s ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA or approval is delayed by patent litigation, that Trevyent is not granted orphan drug exclusivity, the risk that drug development involves a lengthy and expensive process with uncertain outcome, that the company will not satisfy the milestone and other closing conditions to call the second tranche of its July 2016 private placement, that the company will continue to need additional funding, and that the company may be unable to raise capital when needed, which would force the company to delay, reduce or eliminate its product candidate development programs and potentially cease operations. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Annual Report on form 10-K filed on March 29, 2017. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

Contacts:

Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com

The Ruth Group 
Lee Roth
(646) 536-7012
lroth@theruthgroup.com
Friday, March 31st, 2017 Uncategorized Comments Off on $STDY Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

$BVXV Approved for Grant from Israel’s Ministry of Economy and Industry

NESS ZIONA, Israel, March 30, 2017  —

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Israel Investment Center, a unit of the Government of Israel’s Ministry of Economy and Industry, approved a grant representing 20% of a NIS 20M budget to be utilized towards the construction of a factory for the production of Phase 3 and commercial batches of BiondVax’s universal flu vaccine candidate M-001. The grant is subject to certain terms and conditions including those outlined under the Encouragement of Capital Investment Law 1959.

BiondVax plans to build the mid-sized factory in Jerusalem, with potential capacity to annually produce up to tens of millions of doses of M-001. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Five completed Phase 1/2 and Phase 2 human clinical trials have shown the vaccine to be safe and immunogenic to multiple flu strains.

Dr. Ron Babecoff, BiondVax’s CEO, commented, “This significant milestone signifies the evolution of BiondVax from a biotech start-up to a pharmaceutical company positioned for significant growth and contributions to society. I would like to thank the Ministry of Economy and Industry for helping translate BiondVax’s vision to reality.”

Dr. Shimon Hassin, BiondVax’s COO noted, “In the past few years BiondVax focused on establishing a small scale GMP facility, one that was approved by the European Union. Our current facility laid the foundation for manufacturing quality excellence that will be implemented in the new factory.”

An ongoing Phase 2b trial is being conducted in collaboration with the UNISEC consortium. The research has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012. Positive preliminary safety results were announced[1] in November 2016. BiondVax’s consortium partners are continuing to analyze study samples. BiondVax expects the consortium will finalize and release results in Q2 2017.

About BiondVax Pharmaceuticals Ltd

BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit http://www.biondvax.com.

————————————————–

1. http://www.biondvax.com/2016/11/biondvax-phase-2b-trial-preliminary-safety-results-the-universal-flu-vaccine-candidate-is-safe-and-well-tolerated/

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management’s current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the timing and pace of actual receipt of awards, our ability to satisfy conditions to receive the award, adequacy of cash resources generally and specifically to support the construction of the manufacturing facility, the ability to raise captal to support business plan and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.

For further information, please contact:
BiondVax
Joshua Phillipson
Business Development Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com

Thursday, March 30th, 2017 Uncategorized Comments Off on $BVXV Approved for Grant from Israel’s Ministry of Economy and Industry

$XXII Invited to Speak at the Colorado Hemp Expo

22nd Century Group, Inc. (NYSE MKT:XXII), a leader in tobacco harm reduction and cannabis research, announced today that representatives of the Company’s wholly-owned subsidiary, Botanical Genetics, have been invited to serve as featured speakers and presenters at the annual Colorado Hemp Expo at the Ranch Events Complex, 5260 Arena Circle, Loveland, Colorado on Friday, March 31, 2017, and Saturday, April 1, 2017.

Dr. Paul Rushton, Vice President of Plant Biotechnology, and Thomas James, Esq., Vice President & General Counsel, will provide conference attendees with business and scientific updates and highlights of 22nd Century’s advances in the rapidly evolving legal medical marijuana and industrial hemp markets. Headlining the presentation will be Dr. Rushton’s featured speech on Friday evening regarding the Company’s proprietary cannabis initiatives, including the Company’s recently announced development of THC-free industrial hemp plants and the propagation of medical marijuana strains that are selected for increased levels of medically-important cannabinoids, such as CBC and CBD. Dr. Rushton will also speak in a panel discussion on Seeds, Clones, Pesticides and Pollen at the conference. Mr. James will speak on three panel discussions: Investments in Hemp, Global Hemp Activities, and The Future of Hemp. Dr. Rushton, Mr. James and other representatives of the Company will be available for one-on-one meetings throughout the conference.

“We are developing several exciting new strains of medical marijuana as well as industrial hemp varieties with substantially altered levels of cannabinoids – all of which will be below the legal limit of 0.3% THC,” explained Dr. Rushton. “Following our recently announced success with Zero-THC hemp plants and our major collaboration with the University of Virginia, Botanical Genetics is now aggressively expanding our activities in an effort to make our Company a major source of proprietary plants for both the legal medical marijuana and industrial hemp markets. We look forward to exploring exciting business opportunities with like-minded companies in Colorado.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology which allows us to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in cannabis is to develop proprietary cannabis strains for important new medicines and agricultural crops. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. For more information, visit www.xxiicentury.com and www.botanicalgenetics.com.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 8, 2017, including the section entitled “Risk Factors,” and our other reports filed with the U.S Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

 

22nd Century Group, Inc.
Investor Relations:
IRTH Communications
Andrew Haag, 866-976-4784
xxii@irthcommunications.com

Wednesday, March 29th, 2017 Uncategorized Comments Off on $XXII Invited to Speak at the Colorado Hemp Expo

$SGMO New Data Proprietary ZFP Gene Regulation Technology

Engineered Zinc Finger Protein Transcription Factors Lowered Tau Levels by More Than 90% in Human Neurons In Vitro and Reduced Neuritic Dystrophy in Amyloid Mouse Model of Alzheimer’s Disease

RICHMOND, Calif., March 29, 2017  — Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today the presentation of new human in vitro and animal model data demonstrating significant reduction of tau mRNA and tau protein expression using the Company’s zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology. These results are the first evidence of a tau lowering agent demonstrating efficacy on neuritic dystrophy in an amyloid mouse model of Alzheimer’s disease. The data were presented by Sangamo’s collaborators from Massachusetts General Hospital Alzheimer’s Disease Research Center and Harvard Medical School at the 13th International Conference on Alzheimer’s & Parkinson’s Diseases. The meeting is being held in Vienna, Austria from March 29th to April 2nd.

“Tau protein plays a critical role in certain devastating neurodegenerative diseases, including dementias such as Alzheimer’s disease, and studies point to the potential for tau reduction to prevent neuronal loss and possibly even reverse Alzheimer’s disease pathology,” said Bradley Hyman, M.D., Ph.D., Director, Massachusetts Alzheimer’s Disease Research Center and Alzheimer’s Unit Director, MassGeneral Institute for Neurodegenerative Disease at Massachusetts General Hospital, and John B. Penney Jr., Professor of Neurology, Harvard Medical School. “Of the many approaches to reduce tau expression that we’ve studied, zinc finger protein gene regulation technology is especially promising for its exquisite specificity, its potent reduction of tau protein expression, and its potential to provide a durable, long-lasting effect with only a single administration.”

Sangamo’s ZFP-TF gene regulation technology is designed either to selectively repress (down-regulate) or activate (up-regulate) the expression of a specific endogenous gene or gene sequence for a desired therapeutic effect. This approach enables targeting of a broad range of diseases requiring regulation of endogenous gene expression and differs from other approaches such as genome editing or gene therapy, which are designed to correct or replace a missing or mutated gene or gene sequence.

Sangamo intends to seek a partner with disease area expertise for the development and commercialization of its gene regulation approach for Alzheimer’s and other tauopathies.

The March 29th presentation included data from in vitro studies conducted using induced pluripotent stem cell (iPSC) derived neurons demonstrating that a single administration of ZFP-TFs, via adeno-associated virus (AAV) vectors, resulted in greater than 90% reduction of human tau mRNA and protein. These data were consistent with a separate in vitro study using cortical neurons from wild-type mice, in which greater than 90% reduction in tau mRNA and protein was achieved. Furthermore, specificity and off-target analysis in ZFP-TF-treated primary neurons revealed that tau was the only gene suppressed out of more than 26,000 coding transcripts analyzed.

Additionally, data from in vivo studies of wild-type mice demonstrated greater than 80% reduction of tau mRNA and protein in the hippocampus, as well as sustained and well-tolerated ZFP-TF expression with minimal impact on inflammatory markers. Finally, data from in vivo studies in an amyloid mouse model of Alzheimer’s disease demonstrated significantly reduced neuritic dystrophy after a single administration of ZFP-TFs in mice with established disease pathology.

“Our zinc finger protein transcription factor technology continues to demonstrate great potential as a highly differentiated, best-in-class genomic therapy platform for neurodegenerative diseases,” said Michael Holmes, Ph.D., Sangamo’s vice president and head of research. “Zinc finger proteins provide unparalleled precision and potency, which are especially critical for gene-targeting in neurons. Our ZFP-TFs allow us to selectively repress the tau gene which results in significant reduction of all forms of the tau protein, in contrast to other monoclonal antibody-based approaches to Alzheimer’s and tauopathies that bind only to specific forms of tau.”

The repression of tau in both mouse and human neurons is another demonstration of preclinical proof-of-concept for Sangamo’s gene regulation approach for neurodegenerative diseases, which has also been applied to selectively repress the mutant huntingtin allele that causes Huntington’s disease. Sangamo’s huntingtin ZFP-TF specifically targets the mutant CAG-repeat expansion on the disease-causing allele, while preserving the expression of the wild-type huntingtin allele, and has been shown to correct molecular, histopathological and behavioral Huntington’s phenotypes in mouse models of the disease. Sangamo’s ZFP-TF technology is being developed for Huntington’s disease in partnership with Shire.

About Alzheimer’s Disease and Tauopathies

Alzheimer’s disease and other tauopathies are characterized by the accumulation of hyper-phosphorylated tau protein and neurofibrillary tangles in the brain leading to widespread neuronal dysfunction and loss. Intracellular tau protein aggregates and extracellular amyloid plaques are histopathological hallmarks of Alzheimer’s disease. The reduction of tau expression has been shown to provide neuronal protection and reversal of pathology in Alzheimer’s disease and tauopathy models.

About Sangamo Therapeutics 

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients’ lives using the company’s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo is advancing Phase 1/2 clinical programs in hemophilia A and hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has a strategic collaboration with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington’s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company’s website at www.sangamo.com.

Forward Looking Statements

This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation references relating to research and development of therapeutic applications of Sangamo’s zinc finger protein transcription factor technology, the potential of Sangamo’s technology to treat neurodegenerative diseases, including Alzheimer’s and Huntington’s disease, the application of ZFP-TF gene regulation technology to a broad range of diseases, and the ability of Sangamo to enter into partnerships for the development of its technology. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo’s SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo Therapeutics, Inc. assumes no obligation to update the forward-looking information contained in this press release.

Wednesday, March 29th, 2017 Uncategorized Comments Off on $SGMO New Data Proprietary ZFP Gene Regulation Technology

$SGLB PrintRite3D Long Term Commercial Agreement

SANTA FE, N.M., March 29, 2017 — Sigma Labs, Inc. (NASDAQ:SGLB) (“Sigma Labs” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, today announced that it has entered into a long term non-exclusive commercial agreement with Additive Industries B.V. of The Netherlands. As part of the multi-year agreement, anticipated to be worth several million dollars over the next few years, Additive Industries will join Sigma Labs’ previously-announced OEM Partner Program – embedding and reselling Sigma’s PrintRite3D® software within its AM equipment. Additional terms were not disclosed.

Sigma Labs had previously entered into an evaluation period with Additive Industries in late 2015. Additive Industries is developing next-generation metal AM machines that address the demanding applications of high-end industrial markets, and the company launched its MetalFAB1 in the fourth quarter of 2015.

“We are very pleased that Additive Industries has taken the next step in strengthening our long-term relationship by officially joining our OEM Partner Program,” said Mark Cola, President and CEO of Sigma Labs. “Having worked with their esteemed staff for several years, we’ve come to realize the shared value of providing AM machines with the full capabilities of Sigma Labs’ In-Process Quality Assurance™ (IPQA®) applications. By embedding equipment with our PrintRite3D® software before being sold, we can better address the needs of metal component manufacturers across a range of industries and advance the reliability and quality of AM production in real time. We look forward to working with Additive Industries for many years to come.”

About Sigma Labs, Inc.
Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.

About Additive Industries B.V. 
Additive Industries is dedicated to bringing metal additive manufacturing for functional parts from lab to fab by offering a modular 3D printing system and seamlessly integrated information platform to high-end and demanding industrial markets. With substantially improved reproducibility, productivity, and flexibility, Additive Industries redefines the business case for additive manufacturing applications in aerospace, automotive, medical technology and high-tech equipment. Additional information can be found at www.additiveindustries.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements often contain words such as “expects,” “anticipates,” “intends,” “believes” or “will.” These forward-looking statements are subject to a number of risks, uncertainties and assumptions that could adversely affect us, including the risks set forth in Sigma Labs’ most recent annual report on Form 10-K. The forward-looking statements in this press release are made only as of the date of this press release. Sigma Labs undertakes no obligation to update any of these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Chris Witty
cwitty@darrowir.com
646-438-9385
Wednesday, March 29th, 2017 Uncategorized Comments Off on $SGLB PrintRite3D Long Term Commercial Agreement

$INNL FDA Type A on #XARACOLL NDA

ATHLONE, Ireland, March 29, 2017 — Innocoll Holdings plc (NASDAQ:INNL) (“Innocoll” or the “Company”), a global, commercial-stage, specialty pharmaceutical and medical device company, today announced receipt of formal Type A Meeting minutes from the United States Food and Drug Administration (FDA) relating to its New Drug Application (NDA) for XARACOLL (bupivacaine HCl collagen-matrix implant).  XARACOLL is the company’s product in development for the treatment of postsurgical pain.

Innocoll received a Refusal to File (RTF) Letter from the FDA in December 2016 pertaining to the XARACOLL NDA initially submitted on October 31, 2016.  In the RTF letter, the FDA indicated among other things, that XARACOLL should be characterized as a drug/device combination, which would require that the Company submit additional information.  During the Type A meeting, representatives of the FDA, after reviewing information provided by Innocoll to address matters raised in the RTF letter, provided guidance which was confirmed in the formal FDA meeting minutes.  The minutes serve as the official record of the FDA response to our proposal to address certain issues raised in the RTF by conducting an additional short-term pharmacokinetic study and several short-term non-clinical toxicology and biocompatibility studies. Innocoll believes, if adequately financed and successful, such studies may be completed in time for a resubmission of the NDA at the end of 2017.  Data from these studies, along with additional manufacturing information required to address the new combination product designation and other chemistry, manufacturing and control (CMC) issues, are expected to be included in the resubmission.  The acceptability of this data and other data that we reviewed with FDA during the meeting will be evaluated by the FDA during its review of the resubmission.

“I am pleased that we have clarified the data needed to address the questions raised in the RTF letter. With the official minutes from the FDA now in hand, we believe that we have a path forward for a possible resubmission of the XARACOLL NDA by the end of 2017, assuming adequate financing to commence the proposed studies, and further assuming positive results,” said Tony Zook, CEO of Innocoll.

About XARACOLL®

XARACOLL is Innocoll’s late-stage surgically implantable and bioresorbable collagen matrix developed to provide sustained postsurgical pain relief through controlled delivery of bupivacaine at the surgical site.

About Innocoll Holdings plc

Innocoll is a global, commercial stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. Innocoll utilizes its proprietary collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates which can be broken down by the body without the need for surgical removal or topical application.

Responsibility Statement

The Directors of the Company accept responsibility for the information contained in this announcement.  To the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they take responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Forward-looking Statements
Any statements in this press release about our ongoing development of XARACOLL and our other product candidates; our interpretation of the data and results from our MATRIX-1 and MATRIX-2 clinical trials; receiving positive data from additional studies required to submit a revised NDA, our plans for, and the expected timing of, our XARACOLL NDA submission with the FDA; our plans to develop and commercialize XARACOLL and its market potential; the potential therapeutic and other benefits of XARACOLL and our other product candidates; Innocoll’s current expectations regarding future events, including statements regarding the therapeutic benefit, safety profile and commercial value of XARACOLL, plans and objectives for present and future clinical trials and results of such trials, the risk that the FDA may not accept pooled data, plans and objectives for regulatory approval and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties including, but not limited to, the risk that the FDA and foreign regulatory authorities may not agree with our interpretation of the data from our clinical trials of XARACOLL and may require us to conduct additional clinical trials; such additional trials may not result in positive data; XARACOLL may not receive regulatory approval or be successfully commercialized, including as a result of the FDA’s or other regulatory authorities’ decisions regarding limitations on claims that may be made on XARACILL’s label and other matters that could affect its availability or commercial potential; our plans to develop and manufacture XARACOLL;; the size and growth of the potential markets for XARACOLL and our ability to serve those markets; our manufacturing and marketing capabilities; or other actions and factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. In addition, the forward-looking statements included in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  In management’s opinion, and as previously disclosed, Innocoll’s anticipated expenditures during the next 12 months to advance its current operations, including plans to conduct further studies to enable it to submit a revised NDA for XARACOLL and to develop COLLAGUARD will be greater than the amount of its current cash and cash equivalents.  As a result, Innocoll management has been investigating and continues to investigate strategic options for the Company to maximize shareholder value.

The scientific information discussed in this news release related to Innocoll’s product candidates is preliminary and investigative. Such product candidates are not approved by the FDA, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

Rule 8 – Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, “interested” (directly or indirectly) in 1% or more of any class of “relevant securities” of Innocoll, all “dealings” in any “relevant securities” of Innocoll (including by means of an option in respect of, or a derivative referenced to, any such “relevant securities”) must be publicly disclosed by not later than 3.30 pm (Irish time) on the “business day” following the date of the relevant transaction.  This requirement will continue until the date on which the “offer period” ends.  If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an “interest” in “relevant securities” of Innocoll, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.

A disclosure table, giving details of the companies in whose “relevant securities” “dealings” should be disclosed can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie.

“Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities.  In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel’s website.

If you are in any doubt as to whether or not you are required to disclose a “dealing” under Rule 8, please consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 (0)1 678 9020; fax number +353 (0)1 678 9289.

Corporate:
Pepe Carmona
Chief Financial Officer
(215) 983-3362
pcarmona@innocoll.com
Wednesday, March 29th, 2017 Uncategorized Comments Off on $INNL FDA Type A on #XARACOLL NDA

$WKHS to Attend U.S. Department of Transportation 50th Anniversary Ceremony

CINCINNATI, March 29, 2017  — Workhorse Group Inc. (NASDAQ: WKHS), an American technology company focused on providing sustainable and cost-effective solutions to the commercial transportation sector, will attend the U.S. Department of Transportation Welcoming Ceremony and Open House in honor of Secretary Elaine L. Chao and the 50th Anniversary of the Department on Wednesday, March 29, 2017.

“As an innovator in the transportation industry, Workhorse is honored to participate in the celebration of the Department of Transportation’s 50th birthday,” said Steve Burns, CEO of Workhorse. “Over the course of its history, the department has played a key role in moving the transportation industry forward and creating an environment where efficiency, safety and reliability are priorities, just as they are for Workhorse.”

As part of a presentation on the history of transportation to celebrate the 50th anniversary, Workhorse will display its E-GEN electric step van and HorseFly autonomous drone delivery system at the entrance to the Department of Transportation (DOT) at 1200 New Jersey Ave SE, Washington D.C., 20590 from 9 a.m. to 5 p.m.

The electric step vans achieve 30+ miles per gallon equivalent (MPGe) during stop-and-go delivery routes. This electric step van is up to six times as efficient as diesel- or gasoline-powered medium-duty trucks, which typically generate 5-8 miles per gallon. Lower fuel and maintenance costs add up to an estimated $165,000 in total cost-of-ownership savings over 25 years compared to traditional delivery trucks.

The Workhorse HorseFly van-mounted drone has been making successful test deliveries in the United States. The drone is designed to ride on the roof of an electric step van and be an adjunct delivery tool to a driver’s existing delivery methods.

About Workhorse Group Inc.
Workhorse is a technology company focused on providing sustainable and cost-effective solutions to the commercial transportation sector. As an American original equipment manufacturer, we design and build high performance battery-electric vehicles including trucks and aircraft. We also develop cloud-based, real-time telematics performance monitoring systems that are fully integrated with our vehicles and enable fleet operators to optimize energy and route efficiency. All Workhorse vehicles are designed to make the movement of people and goods more efficient and less harmful to the environment.

Forward-Looking Statements
This press release includes forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future to fulfill product orders; risks associated with obtaining orders and executing upon such orders; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our inability to maintain our listing of our securities on the Nasdaq Capital Market; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission (“SEC”), including our annual report on Form 10-K filed with the SEC. Workhorse expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Wednesday, March 29th, 2017 Uncategorized Comments Off on $WKHS to Attend U.S. Department of Transportation 50th Anniversary Ceremony

$ATHX to Present at Needham Healthcare Conference on April 4

CLEVELAND, March 29, 2017 — Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central Hotel in New York City.  The presentation is scheduled for Tuesday, April 4, 2017 at 12:10 pm ET.

Investors interested in arranging a meeting with the Company’s management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.athersys.com. An archived replay of the webcast will be available for 90 days on the Company’s website after the conference.

About Athersys

Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

ATHX-G

Contact:

William (B.J.) Lehmann, J.D.		
President and Chief Operating Officer			
Tel: (216) 431-9900			
bjlehmann@athersys.com

David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
David.schull@russopartnersllc.com

Investor Contact:
Peter Vozzo
Westwicke Partners
(443) 213-0505 or (443) 377-4767 (mobile)
Peter.vozzo@westwicke.com
Wednesday, March 29th, 2017 Uncategorized Comments Off on $ATHX to Present at Needham Healthcare Conference on April 4

$DRWI noxville Utilities Board Selects DragonWave for Smart Grid

OTTAWA, CANADA–(March 28, 2017) – DragonWave Inc. (TSX:DRWI)(NASDAQ:DRWI) a global supplier of packet microwave radio systems, today announced the selection of the Harmony Enhanced MC backhaul solution by Knoxville Utilities Board (KUB). KUB is an independent agency of the City of Knoxville that provides electricity, gas, water and water waste services to customers in Knoxville and parts of seven surrounding counties (Over 750 square miles). This deployment will increase available bandwidth, reduce overall network operation and maintenance (O&M) costs and improve reliability of the overall field network.

DragonWave’s Harmony Enhanced MC will extend KUB’s existing fiber/wireline facilities to create a hybrid wireless and wireline network. KUB will use Harmony Enhanced MC to create fiber type connections via wireless, through the radios ability to support multiple channels with high modulation (up to 2048 QAM) in one small form factor.

Peter Cappiello, Future Technologies, President and CEO, “By selecting Dragonwave’s Harmony Enhanced MC for our bid, we were able to reach and exceed the capacity and reliability values required using 3′ antennas instead of comparison examples that would have required 6′ antennas. Each 1′ of antenna reduction decreased the potential for new tower requirements (CAPEX), as well as the re-occurring costs associated with larger dishes (OPEX), which made the decision simple for KUB.”

The DragonWave Harmony Enhanced MC is a high capacity microwave solution that enables customers to deliver 1 Gbps of uncompressed throughput in a single radio (using 50MHz channels) and up to 2 Gbps per radio with the industry leading Bandwidth Accelerator+ bulk compression feature. Harmony Enhanced MC also delivers the highest system gain in the industry, allowing customers to maximize capacity and minimize antenna sizes on longer links.

“Harmony Enhanced MC is to deliver the backbone for internet of things (IoT) networks through its ability to re-use existing infrastructure locations with its market leading technology to keep antenna sizes as small as possible to allow for installation at these points,” said Peter Allen, DragonWave President and CEO. “We are pleased to be able to provide this solution to KUB and the utilities and industrial markets as a whole.”

WEBINAR – If you are interested in hearing more about this utility use case, please join our utility focused webinar on April 5, 2017 at 2 pm EST being conducted with Future Technologies and UTC (Utilities Technology Council) – Please use this link.

About DragonWave

DragonWave® is a leading provider of high-capacity packet microwave solutions that drive next-generation IP networks. DragonWave’s carrier-grade point-to-point packet microwave systems transmit broadband voice, video and data, enabling service providers, government agencies, enterprises and other organizations to meet their increasing bandwidth requirements rapidly and affordably. The principal application of DragonWave’s portfolio is wireless network backhaul, including a range of products ideally suited to support the emergence of underlying small cell networks. Additional solutions include leased line replacement, last mile fiber extension and enterprise networks. DragonWave’s corporate headquarters is located in Ottawa, Ontario, with sales locations in Europe, Asia, the Middle East and North America. For more information, visit http://www.dragonwaveinc.com.

About Knoxville Utilities Board

The Knoxville Utilities Board (“KUB”) exists under the laws of the State of Tennessee and is an independent agency of the City of Knoxville. KUB provides electricity, gas, water, and wastewater services to customers in Knoxville and parts of seven surrounding counties. KUB’s service territory covers an area of over 750
square miles. Throughout this service territory are areas with varying combinations of services. Visit – www.kub.org

About Future Technologies Venture, LLC (Future Technologies)

Future Technologies is a professional services company specializing in the assessment, planning, design, implementation, and support of innovative communications solutions focused on wireless infrastructures and their accompanying technologies for commercial and military customers around the world. Maintaining a strong concentration on emerging standards such as 4G technologies; which include WiMax (Fixed and Mobile) and LTE (Long Term Evolution) products, as well as established cellular (EVDO, GSM, and CDMA) and Fixed Wireless Backhaul solutions, Future Technologies consistently distinguishes itself as an industry expert in all aspects of customer network evolution. Future Technologies is headquartered in Atlanta, GA. Visit – www.futuretechllc.com

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to DragonWave’s growth opportunities and the potential benefits of, and demand for, DragonWave’s products. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of DragonWave’s products compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. DragonWave’s actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of DragonWave to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by DragonWave with U.S. and Canadian securities regulatory authorities. DragonWave assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Media Contact:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
+1-613-599-9991 ext 2262

Investor Contact:
Pat Houston
CFO
DragonWave Inc.
pallen@dragonwaveinc.com
+1-613-599-9991

Tuesday, March 28th, 2017 Uncategorized Comments Off on $DRWI noxville Utilities Board Selects DragonWave for Smart Grid

$CRSP Announces European Patent for CRISPR/Cas Gene Editing

– Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells

BASEL, Switzerland, March 28, 2017  — CRISPR Therapeutics (NASDAQ:CRSP) reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The claims are directed to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including in cells from vertebrate animals such as human or mammalian cells – as well as composition claims for use in any setting, including claims for use in a method of therapeutic treatment of a patient.

“We’re very pleased with the decision by the European Patent Office recognizing the broad applicability of our foundational IP, and we look forward to pursuing additional cases to grant in other jurisdictions globally,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics.

The European patent application (No. 13793997) was the subject of numerous third-party observations or ‘TPOs’ filed by the Broad Institute and others attempting to prevent or delay its grant. Following review of those submissions, the EPO determined that the technical evidence and associated legal arguments did not alter patentability of the inventions by the applicants, and accordingly announced its intention to advance the case to grant in Europe. The full EPO case files, TPOs, and claims intended for grant are available on-line via the EPO’s official website at https://register.epo.org/application?number=EP13793997.

The underlying international patent application is based on the same U.S. priority application that has been involved in an interference proceeding with the Broad et al., which priority application (USSN 61/652086) was filed on May 25, 2012, on behalf of CRISPR’s co-founder Dr. Emmanuelle Charpentier (currently a director at the Max-Planck Institute in Berlin) along with the Regents of the University of California and University of Vienna.

The United Kingdom’s Intellectual Property Office (UKIPO) has also examined the related applications, and likewise considered technical evidence and arguments submitted by third parties, before ultimately reaching similar conclusions to those of the EPO. The UKIPO granted a first UK Patent to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings (No. 2518764), and a second UK Patent to ‘chimeric’ CRISPR/Cas9 systems in which the Cas9 protein is modified to provide alternative DNA-modulating activities (No. 2537000).

“We and the licensors of these foundational cases for CRISPR/Cas9 gene editing have long appreciated that Emmanuelle Charpentier along with Jennifer Doudna and their doctoral and post-doctoral colleagues provided innovations that facilitated the CRISPR field,” said Dr. Tyler Dylan-Hyde, Chief Legal Officer of CRISPR Therapeutics. “We also appreciate that despite attempts by third parties to delay or prevent these grants through TPOs or potential oppositions, patent offices are beginning to recognize both the fundamental significance of the teachings by the Charpentier-Doudna team and their wide applicability to CRISPR/Cas gene editing,” noted Dr. Dylan-Hyde. “We look forward to pursuing similar findings in the U.S. under the first-to-invent system – and throughout the approximately 80 other countries our filings cover worldwide, including Europe, all of which are on a first-to-file priority system.”

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Dr. Emmanuelle Charpentier.  CRISPR Therapeutics is headquartered in Basel, Switzerland, with offices in London, United Kingdom, and R&D operations in Cambridge, Massachusetts.  For more information, please visit www.crisprtx.com.

Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies and the intellectual property protection of our technology and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; uncertainties inherent in the initiation and completion of preclinical studies for the Company’s product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release.

 

Media Contact:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 
jpaganelli@wcgworld.com

Investor Contact:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 
chris.brinzey@westwicke.com
Tuesday, March 28th, 2017 Uncategorized Comments Off on $CRSP Announces European Patent for CRISPR/Cas Gene Editing

$MTNB to Ring NYSE Closing Bell on March 29th, 2017

BEDMINSTER, N.J., March 28, 2017 — Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Roelof Rongen, Co-Founder and Chief Executive Officer, will ring the NYSE Closing Bell on Wednesday, March 29, 2017 at 4:00 p.m. ET. Members of the Matinas executive management team and Board of Directors will join Mr. Rongen at the New York Stock Exchange to celebrate the Company’s recent approval for listing on the NYSE MKT.

The New York Stock Exchange will stream the closing bell ringing on its website: https://www.nyse.com/bell. A video of the event will also be archived on that same page after the livestream.

About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company’s proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company’s lead drug candidate MAT2203, currently in Phase 2, is an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). MAT2501, the Company’s orally-administered encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections, reported positive topline data from the Phase 1 single-ascending dose study in healthy volunteers. Matinas is advancing its MAT2501 Phase 1 program in preparation of a Phase 2 study in patients.

The Company’s lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s strategic focus and the future development of its product candidates, including MAT2203 and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations for MAT2203 and MAT2501, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

 

Investor Contact
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jenene@jenenethomascommunications.com
Tuesday, March 28th, 2017 Uncategorized Comments Off on $MTNB to Ring NYSE Closing Bell on March 29th, 2017

$XRA to be Acquired by $GG

VANCOUVER, B.C., March 28, 2017 — Exeter Resource Corporation (NYSE-MKT:XRA) (TSX:XRC) (Frankfurt:EXB) (“Exeter” or the “Company”) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Goldcorp Inc. (NYSE:GG) (TSX:G) (“Goldcorp”), whereby Goldcorp will acquire all of the outstanding shares of Exeter under a plan of arrangement for consideration of 0.12 of a Goldcorp share for each Exeter share, which represents a value equivalent to C$2.58 per Exeter share, based on the closing price of Goldcorp shares on the TSX on March 27, 2017, and total consideration of C$247 million.

This represents a premium of 67% on the Exeter shares based on the closing prices of both companies common shares on the TSX on March 27, 2017 and a 60% premium based on Goldcorp’s and Exeter’s 20‐day TSX volume weighted average trading price ending on March 27, 2017.

Exeter’s Board of Directors has unanimously approved the transaction and recommends that Exeter shareholders vote in favour of the arrangement. All of the directors and officers of Exeter, who own or control approximately 8.4% of Exeter’s issued and outstanding shares, have entered into support agreements with Goldcorp pursuant to which they have agreed, among other things, to support the transaction and vote their Exeter shares in favour of the arrangement.

Scotiabank and Paradigm Capital Inc., have provided opinions to the Exeter Board of Directors and the special committee of independent directors of Exeter, respectively, that as of the date of such opinions and subject to the assumptions, limitations, and qualifications stated in such opinions, the consideration to be received by the Exeter shareholders under the transaction is fair, from a financial point of view, to the Exeter shareholders (other than Goldcorp and its affiliates).

Benefits to Exeter Shareholders

  • Secures immediate value appreciation for Exeter shareholders, eliminating the burden of future dilution as would be necessary to move the Caspiche project forward.
  • Based on March 27, 2017 closing prices, the 0.12 of a Goldcorp share offered for each Exeter share represents
    – Total consideration of approximately C$247 million, or C$2.58 per share.
    – Premium of 67% to Exeter’s closing share price on March 27, 2017.
    – Premium of 60% to the volume weighted average trading price of Exeter shares on the TSX for the 20-day period ending on March 27, 2017.
  • Goldcorp is the world’s fourth largest gold producer, with high-quality, low-cost production and an investment grade balance sheet.
  • Conversion of Exeter shares to Goldcorp shares provides exposure to Goldcorp’s portfolio of diversified, world-class assets in low political risk jurisdictions.
  • Goldcorp with its joint venture partner in the Maricunga Gold Belt, Barrick Gold Corporation (TSX:ABX) (NYSE:ABX) have the technical and financial capability to advance the Caspiche project to production at a scale commensurate with the size of the available resources.

Co-Chairman of Exeter, Yale Simpson stated, “Since the discovery of Caspiche in 2007, our team successfully delineated and technically advanced one of the largest gold – copper deposits in the Americas. While advancing the near surface 1.7 million ounce gold oxide open pit is a sensible starter option for Exeter, the enormous scope of the Caspiche gold-copper sulphide project requires both the capital and technical expertise of a major mining company to unlock its true value. Goldcorp, a leading gold producer with a strong track record of responsible mining is both capable and motivated to develop a mine at Caspiche. Exeter shareholders receive an immediate, attractive premium in this transaction. Through the Goldcorp shares received they retain their exposure to the Caspiche project, but without the adherent financial risk that would challenge Exeter.”

Closing of the transaction is subject to various conditions, which are standard for a transaction of this nature, including receipt of Exeter shareholder, court and regulatory approval. Full details of the transaction will be set out in Exeter’s information circular that it will prepare in respect of the meeting of shareholders to approve the transaction, to be held on or before May 31, 2017. Exeter intends to mail the information circular by mid-April, 2017. The transaction is expected to close no later than June 30, 2017.

Pursuant to the arrangement, Exeter is subject to customary non-solicitation covenants. In the event a superior proposal is made to Exeter, Goldcorp has the right to match such proposal. Under certain circumstances where the transaction is not completed, Exeter has agreed to pay a termination fee of C$8.65 million to Goldcorp.

Exeter has engaged Scotiabank as its financial advisor and Gowling WLG (Canada) LLP in Canada, Dorsey & Whitney LLP in the United States, and Bofill Mir & Álvarez Jana in Chile as its legal advisors in connection with the transaction.

Copies of the Agreement, support agreements, management information circular, when available, and certain related documents will be filed with securities regulators and will be available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

None of the securities to be issued pursuant to the Arrangement Agreement have been, or will be registered under the United State Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable securities law of any state of the United States and may not be offered or sold in the United States or to, or for the account or benefit of a U.S. person, absent such registration or an exemption therefrom.  It is anticipated that any securities to be issued under the Arrangement will be offered and issued in reliance upon the exemption from such registration requirements provided by Section 3(a)(10) of the U.S. Securities Act and pursuant to applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

About Exeter Resource Corporation:

Exeter is a Canadian mineral exploration company focused on the exploration and development of the Caspiche project in Chile. Caspiche is well located in Chile’s Maricunga district, which has good infrastructure and is in close proximity to other large scale mining operations and projects in development.

About Goldcorp:

Goldcorp is a senior gold producer focused on responsible mining practices with safe, low-cost production from a high-quality portfolio of mines.

For further information about Goldcorp, please visit their website at www.goldcorp.com

On behalf of Exeter Resource Corp,
Mr. Wendell M. Zerb, P. Geol
President & Chief Executive Officer

Safe Harbour Statement – This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward-looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including in relation to management’s assessment of the benefits to shareholders of the proposed transaction with Goldcorp, anticipated mailing and meeting days, timing for completion of the transaction, the Company’s belief as to the potential significance of water discovered and the potential to utilize the desalinated water secured under option, the timing and completion of a new preliminary economic assessment or other studies for the advancement of Caspiche, including a production decision on the oxide project, the potential to establish new opportunities for the advancement of Caspiche, results from the 2014 PEA including estimated annual production rates, capital and production costs or expected changes to such costs, water and power requirements and metallurgical recoveries, expected taxation rates, potential for securing water rights and adequate water and potential approval of water extraction, potential for reduced power costs, potential to acquire new projects and expected cash reserves. These forward-looking statements are made as of the date of this news release. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur.  While the Company has based these forward-looking statements on its expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements. Such factors and assumptions include, among others, the receipt of all shareholder and regulatory approvals, no undue delays with respect to the transaction, effects of general economic conditions, the price of gold, silver and copper, changing foreign exchange rates and actions by government authorities, uncertainties associated with negotiations and misjudgments in the course of preparing forward-looking information. In addition, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Known risk factors include risks associated with failure to complete the transaction, project development; including risks associated with the failure to satisfy the requirements of the Company’s agreement with Anglo American on its Caspiche project which could result in loss of title; the need for additional financing; operational risks associated with mining and mineral processing; risks associated with metallurgical recoveries, risks associated with operating in areas subject to drought conditions and scarcity of available water sources, power availability and changes in legislation affecting the use of those resources; fluctuations in metal prices; title matters; uncertainty and risks associated with the legal challenge to the easement secured from the Chilean government; uncertainties and risks related to carrying on business in foreign countries; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain officers, directors or promoters of the Company with certain other projects; the absence of dividends; currency fluctuations; competition; dilution; the volatility of the Company’s common share price and volume; tax consequences to U.S. investors; and other risks and uncertainties, including those described herein and in the Company’s Annual Information Form for the financial year ended December 31, 2016 dated March 24, 2017 filed with the Canadian Securities Administrators and available at www.sedar.com and filed with the SEC as part of the Company’s annual report on Form 40-F available at www.sec.gov.  Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company is under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

Cautionary Note to United States Investors – Exeter is required to describe mineral resources associated with its properties utilizing Canadian Institute of Mining, Metallurgy and Petroleum (“CIM”) definitions of “measured mineral resources”, “indicated mineral resources” and “inferred mineral resources” are defined in and are required to be disclosed pursuant to Canadian regulations; however, these terms are not defined terms under the United States Securities and Exchange Commission’s Industry Guide 7 and normally are not permitted to be used in reports and other documents filed with the SEC. Investors are cautioned not to assume that any part or all of mineral deposits in these categories will ever be converted into SEC Industry Guide 7 compliant mineral reserves. “Inferred mineral resources” have a great amount of uncertainty as to their existence and as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Under Canadian rules, estimates of inferred mineral resources may not form the basis of feasibility or pre-feasibility studies, except in rare cases. Disclosure of “contained ounces” in a mineral resource is permitted disclosure under Canadian regulations. However, the SEC normally only permits issuers to report mineralization that does not constitute “mineral reserves” by SEC Industry Guide 7 standards as in place tonnage and grade, without reference to unit measures. Accordingly, information contained in this press release or referenced herein containing descriptions of mineral deposits may not be comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements under the United States federal securities laws and the rules and regulations thereunder, including SEC Industry Guide 7.

NEITHER THE TSX NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE

For further information, please contact:
Wendell Zerb, CEO or 
Rob Grey, VP Corporate Communications
Tel: 604.688.9592  Fax: 604.688.9532
Toll-free: 1.888.688.9592

Suite 1660, 999 West Hastings St.
Vancouver, BC Canada  V6C 2W2
exeter@exeterresource.com
Tuesday, March 28th, 2017 Uncategorized Comments Off on $XRA to be Acquired by $GG

$AKER Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check

THOROFARE, NJ–(Mar 28, 2017) – Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the “Company” or “Akers Bio”), a developer of rapid health information technologies, has received an initial order for the Company’s rapid cholesterol self-test from First Check Diagnostics, LLC (“First Check”), the exclusive distributor for this product in the United States, for sale under their popular “First Check” brand.

First Check products are sold through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo.

Akers Bio’s Tri-Cholesterol “Check” test is the only combined rapid test which provides an estimate of a person’s Total cholesterol as well as their High Density Lipoprotein (“HDL”) cholesterol levels – their ‘good cholesterol’; thereby providing an estimate of a person’s Low Density Lipoprotein (“LDL”) levels – their ‘bad cholesterol’. These features are essential to accurately differentiating between a person’s ‘good’ and ‘bad’ cholesterol thereby making it a truly effective screening test for high cholesterol.

The Tri-Cholesterol “Check” test is disposable, uses just a finger-stick blood sample and gives a result in only 5 minutes. The test has FDA 510(k) clearance in the United States; as well as a CE mark for the European Economic Area.

According to the United States Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the United States have high ‘bad cholesterol’ and less than 1 in every 3 of them has the condition under control. Too much cholesterol puts people at risk for heart disease and stroke, two leading causes of death in the United States. However, with responsible actions such as self-testing with Akers Bio’s Tri-Cholesterol “Check” test, people can take steps to manage their cholesterol levels and lower their risk.

John J. Gormally, Chief Executive Officer of Akers Bio, commented: “I am delighted that we will soon have this over-the-counter health and wellness product from Akers Bio on the shelves of major US retailers under the distinguished First Check brand. It is a great endorsement of our rapid testing technology. We look forward to building this revenue stream with our distribution partner and providing people in America with a fast, convenient and meaningful way to evaluate and manage their cholesterol, which is a serious concern for millions of people.”

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698

finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500

Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com

Tuesday, March 28th, 2017 Uncategorized Comments Off on $AKER Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check

$CBIO IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program

— Investigational New Drug (IND) approval from Korean Ministry of Food and Drug Safety represents a key milestone in Catalyst’s Factor IX development program —

— Catalyst’s collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017 —

SOUTH SAN FRANCISCO, Calif., March 28, 2017  — Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304. Hemophilia is a serious bleeding disorder that results in spontaneous bleeding episodes as well as substantially prolonged bleeding times upon injury.

CB 2679d/ISU304, a highly potent next-generation coagulation Factor IX variant, has demonstrated the potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. Catalyst’s collaborator, ISU Abxis (KOSDAQ:086890), plans to initiate a Phase 1/2 proof-of-concept study with single and multiple subcutaneous injections in individuals with severe hemophilia B in the second quarter of 2017.

“We are very pleased with the progress we and our collaborator ISU Abxis have made in advancing this Factor IX candidate towards the clinic and we look forward to the initiation of a Phase 1/2 clinical trial next quarter,” said Nassim Usman, Ph.D., President and Chief Executive Officer of Catalyst. “We believe that stopping bleeding is good, but preventing bleeding is better. CB 2679d/ISU304 has the properties required, including high potency, to allow for daily subcutaneous injection with the potential to achieve stable and normal Factor IX clotting levels.”

Catalyst has a collaboration with ISU Abxis to advance the development of CB 2679d/ISU304 through a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B. After Phase 1/2, ISU Abxis has an option for exclusive commercial rights in South Korea and a profit share on ex-South Korean commercialization. Catalyst retains full development and commercial rights for CB 2679d/ISU304 outside of South Korea.

About Factor IX
CB 2679d/ISU304 is a next-generation coagulation Factor IX variant that is IND-approved in South Korea. CB 2679d/ISU304 has exhibited enhanced procoagulant activity, improved efficacy in inhibiting blood loss, and prolonged duration of action in bleeding and non-bleeding preclinical models compared with other Factor IX products on the market. Catalyst believes that CB 2679d/ISU304 may allow for subcutaneous prophylactic treatment of individuals with hemophilia B.

About Hemophilia and Factor Replacement Therapy
Hemophilia, for which there is no cure, is a rare but serious bleeding disorder that results from a genetic or an acquired deficiency of a protein required for normal blood coagulation. There are two major types of hemophilia, A and B, that are caused by alterations in Factor VIII or Factor IX genes, respectively, with a corresponding deficiency in the affected proteins. The prevalence of hemophilia A and B in the United States is estimated to be around 20,000 people, with more than 400,000 cases worldwide. Individuals with hemophilia suffer from spontaneous bleeding episodes as well as substantially prolonged bleeding times upon injury. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in permanent, disabling joint damage and can become life threatening. Treatment usually involves management of acute bleeding episodes or prophylaxis through factor replacement therapy by infusion of patients’ missing Factor VIII or IX. With the frequent infusion schedule of current therapies, adherence is difficult. In addition, convenient access to peripheral veins is often a problem, and many children require use of central venous access devices, with the concomitant risks of infection and thrombosis.

About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. Catalyst’s most advanced program is a potent next-generation coagulation Factor VIIa variant, marzeptacog alfa (activated), that has successfully completed an intravenous Phase 1 clinical trial in individuals with severe hemophilia A or B. Catalyst is also developing a next-generation Factor IX variant, CB 2679d/ISU304, that is IND-approved in Korea. For more information, please visit www.catalystbiosciences.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, the potential uses and benefits of CB 2679d/ISU304 and marzeptacog alfa (activated), and development plans for these product candidates are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Catalyst’s clinical trial timelines, including the anticipated initiation two trials in 2017, the potential uses and benefits of subcutaneously dosed CB 2679d/ISU304 and marzeptacog alfa (activated), ISU Abxis’ plans to initiate a Phase 1/2 proof-of-concept study, and the potential for CB 2679d/ISU304 to allow for subcutaneous prophylactic treatment of individuals with hemophilia B and to achieve stable and normal Factor IX clotting levels. Actual results or events could differ materially from the plans, expectations and projections disclosed in these forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that human trials will not replicate the results from animal studies, that potential adverse effects may arise from the testing or use of Catalyst’s products, including the generation of antibodies, the risk that costs required to develop or manufacture Catalyst’s products will be higher than anticipated, competition, and other factors described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and S-1 filed with the SEC. Catalyst does not assume any obligation to update any forward-looking statements, except as required by law.

Contacts:

Investors:
Fletcher Payne, CFO
Catalyst Biosciences
650.871.0761
investors@catbio.com 

Media:
Denise Powell
510.703.9491
denise@redhousecomms.com
Tuesday, March 28th, 2017 Uncategorized Comments Off on $CBIO IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program

$NXTD and Fit Pay, Inc. Announce Letter of Intent to Combine Their Businesses

MELBOURNE, Florida, March 27, 2017 —

Potential Transaction Would add a Comprehensive Payment and Authentication Platform to NXT-ID’s Existing Products and Capabilities

NXT-ID, Inc. (NASDAQ: NXTD) (“NXT-ID” or the “Company”), a security technology company, and Fit Pay, Inc., a privately held provider of payment, credential management, and authentication platform services, today announced that the companies have entered into Letter of Intent to combine their businesses in a deal that includes stock and cash consideration. NXT-ID will not be raising additional capital to complete this transaction.

“This potential transaction with Fit Pay would not only add a critical component to our payment and authentication products, but also a platform which will enable a whole new suite of offerings including payments, credential management, and secure authentication services,” said Gino Pereira, Chief Executive Officer of NXT-ID, Inc. “Fit Pay’s leadership team has over 50 years of experience in the payment space. The completion of this transaction would provide an important addition to our business model, increasing our opportunities with existing products and allowing us to rapidly expand in digital payments and the Internet of Things (IoT), both of which are part of our strategic plan.”

Fit Pay is a white-label technology platform that provides payment, credential management, authentication, capabilities and other secure services to wearable and IoT devices. Fit Pay has integrated with the major credit card networks and chip manufacturers to provide an all-in-one solution and flexible integration options with developer-friendly tools and documentation, including Trusted Service Management services, full-featured API, mobile SDK (iOS & Android) and a highly secure payment network tokenization scheme.

“Blending our payment and authentication capabilities with NXT-ID’s industry-leading technology products will significantly accelerate our ability to capture market share,” said Michael Orlando, CEO of Fit Pay, Inc. “As consumers interact with more and more devices, providing core secure services with the confidence of knowing the user has been authenticated is critical. NTX-ID and Fit Pay create a powerful combination that will do just that – offering transformational products and services to the marketplace.”

The transaction remains subject to completion of due diligence reviews, customary definitive documentation and Nasdaq review. The companies seek to complete the transaction early in the second quarter of 2017.

About NXT- ID Inc. – Mobile Security for a Mobile World

NXT-ID, Inc. (NASDAQ: NXTD) is a security technology Company providing security for finance, assets, and healthcare. The Company’s innovative MobileBio® solution mitigates risks associated with mobile computing, m-commerce, and smart OS-enabled devices. With extensive experience in biometric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, the Company partners with industry leading companies to provide solutions for modern payment and the Internet of Things (“IoT”) applications. The Company’s wholly owned subsidiary, LogicMark, LLC, manufactures and distributes non-monitored and monitored personal emergency response systems (“PERS”) sold through the United States Department of Veterans Affairs (“VA”), healthcare durable medical equipment dealers and distributors and monitored security dealers and distributors. http://www.nxt-id.com

About Fit Pay, Inc.

Based in San Francisco, California, Fit Pay, Inc. is led by former CyberSource and Visa executives with more than 50 years of payment and identity authentication domain expertise. With payment capabilities enabled by Fit Pay, wearable and IoT device manufacturers can create customer loyalty, tap into recurring revenue streams, open new markets, and differentiate their products in an increasingly competitive market. The company was named a “Cool Vendor” by Gartner for 2016. Learn more at http://www.fit-pay.com, or on Twitter.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from other patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

NXT-ID Inc. Contact:
Corporate info: info@nxt-id.com

Media:
D. Van Zant
+1-800-665-0411
press@nxt-id.com

Fit Pay, Inc. Contact:
Chris Orlando
+1-760-468-7273
chris@fit-pay.com

Monday, March 27th, 2017 Uncategorized Comments Off on $NXTD and Fit Pay, Inc. Announce Letter of Intent to Combine Their Businesses